The highs and lows of cannabinoid drug development

"So as not to disappoint you (please see the following presentation by Professor David Baker); we are still trying to develop drugs for MS'ers. In this case we are targeting spasticity as the current drugs we have for spasticity are far from ideal and cause too many side effects; for example sedation, wearing-off spasms and the rag-doll effect (weakness)." 


CoI: Multiple